Blood Test Can Rapidly Detect Infection Risk
By LabMedica International staff writers Posted on 11 Dec 2013 |

Image: Microfluidic device for six assays under the microscope (Photo courtesy of BioMEMS Resource Center).
A device has been created that is able to detect a person's risk of infection from a drop of blood within minutes, as opposed to current methods, which can take up to two hours.
Neutrophil chemotaxis is critical for defense against infections and its alterations could lead to chronic inflammation and tissue injury and the central role that transient alterations of neutrophil chemotaxis could have on patient outcomes calls for its quantification in the laboratory.
Scientists at the Massachusetts General Hospital (Boston, MA, USA) designed a microfluidic device to study neutrophil chemotaxis from a single droplet of whole blood, which has three main components: a chemokine side chambers (200 × 200 μm), a central whole-blood loading chamber, and migration channels containing red blood cell (RBC) filtering regions.
The filter for each migration channel consists of 10 short channels (length about 75 μm) connected horizontally through an approximately 200-μm-long channel to create 90 degree bending sections capable of trapping the RBCs in order to prevent them from dispersing into the rest of the migration channel. A gradient of the chemoattractant is established along the migration channels by diffusion between the chemoattractant chambers and the central loading chamber.
The assay was validated by comparing neutrophil chemotaxis from finger prick, venous blood and purified neutrophil samples. There was a consistent average velocity of 19 ± 6 μm/minute and directionality of 91.1% between the three sources. The team quantified the variability in neutrophil chemotaxis between healthy donors and found no significant changes over time. The novel whole blood device was also used to monitor neutrophil chemotaxis function in a patient with 24% total body surface area burns over a three-week treatment period.
Daniel Irmia, MD, PhD, an assistant professor at the BioMicro Electrical Mechanical Systems Resource Center (BioMEMS; Boston, MA, USA) and a senior author of the study said, “In many cases, it may not be enough to just count the neutrophils. If neutrophils do not migrate well and cannot reach inside the tissues, this situation could have the same consequences as a low neutrophil count.” The authors concluded that being able to measure patients' risk of infections in a matter of minutes from only a droplet of blood is a significant development and one that will improve current treatment. The study was published on October 2, 2013, in the journal Technology.
Related Links:
Massachusetts General Hospital
BioMEMS Resource Center
Neutrophil chemotaxis is critical for defense against infections and its alterations could lead to chronic inflammation and tissue injury and the central role that transient alterations of neutrophil chemotaxis could have on patient outcomes calls for its quantification in the laboratory.
Scientists at the Massachusetts General Hospital (Boston, MA, USA) designed a microfluidic device to study neutrophil chemotaxis from a single droplet of whole blood, which has three main components: a chemokine side chambers (200 × 200 μm), a central whole-blood loading chamber, and migration channels containing red blood cell (RBC) filtering regions.
The filter for each migration channel consists of 10 short channels (length about 75 μm) connected horizontally through an approximately 200-μm-long channel to create 90 degree bending sections capable of trapping the RBCs in order to prevent them from dispersing into the rest of the migration channel. A gradient of the chemoattractant is established along the migration channels by diffusion between the chemoattractant chambers and the central loading chamber.
The assay was validated by comparing neutrophil chemotaxis from finger prick, venous blood and purified neutrophil samples. There was a consistent average velocity of 19 ± 6 μm/minute and directionality of 91.1% between the three sources. The team quantified the variability in neutrophil chemotaxis between healthy donors and found no significant changes over time. The novel whole blood device was also used to monitor neutrophil chemotaxis function in a patient with 24% total body surface area burns over a three-week treatment period.
Daniel Irmia, MD, PhD, an assistant professor at the BioMicro Electrical Mechanical Systems Resource Center (BioMEMS; Boston, MA, USA) and a senior author of the study said, “In many cases, it may not be enough to just count the neutrophils. If neutrophils do not migrate well and cannot reach inside the tissues, this situation could have the same consequences as a low neutrophil count.” The authors concluded that being able to measure patients' risk of infections in a matter of minutes from only a droplet of blood is a significant development and one that will improve current treatment. The study was published on October 2, 2013, in the journal Technology.
Related Links:
Massachusetts General Hospital
BioMEMS Resource Center
Latest Technology News
- Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
- Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
- Smartphones Could Diagnose Diseases Using Infrared Scans
- Novel Sensor Technology to Enable Early Diagnoses of Metabolic and Cardiovascular Disorders
- 3D Printing Breakthrough Enables Large Scale Development of Tiny Microfluidic Devices
- POC Paper-Based Sensor Platform to Transform Cardiac Diagnostics
- Study Explores Impact of POC Testing on Future of Diagnostics
- Low-Cost, Fast Response Sensor Enables Early and Accurate Detection of Lung Cancer
- Nanotechnology For Cervical Cancer Diagnosis Could Replace Invasive Pap Smears
- Lab-On-Chip Platform to Expedite Cancer Diagnoses
- Biosensing Platform Simultaneously Detects Vitamin C and SARS-CoV-2
- New Lens Method Analyzes Tears for Early Disease Detection
- FET-Based Sensors Pave Way for Portable Diagnostic Devices Capable of Detecting Multiple Diseases
- Paper-Based Biosensor System to Detect Glucose Using Sweat Could Revolutionize Diabetes Management
- First AI-Powered Blood Test Identifies Patients in Earliest Stage of Breast Cancer
- Optical Biosensor Rapidly Detects Monkeypox Virus at Point of Care
Channels
Clinical Chemistry
view channel
Carbon Nanotubes Help Build Highly Accurate Sensors for Continuous Health Monitoring
Current sensors can measure various health indicators, such as blood glucose levels, in the body. However, there is a need to develop more accurate and sensitive sensor materials that can detect lower... Read more
Paper-Based Device Boosts HIV Test Accuracy from Dried Blood Samples
In regions where access to clinics for routine blood tests presents financial and logistical obstacles, HIV patients are increasingly able to collect and send a drop of blood using paper-based devices... Read moreMolecular Diagnostics
view channel
RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms
Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more
First Of Its Kind Test Uses microRNAs to Predict Toxicity from Cancer Therapy
Many men with early-stage prostate cancer receive stereotactic body radiotherapy (SBRT), a highly precise form of radiation treatment that is completed in just five sessions. Compared to traditional radiation,... Read more
Novel Cell-Based Assay Provides Sensitive and Specific Autoantibody Detection in Demyelination
Anti-myelin-associated glycoprotein (MAG) antibodies serve as markers for an autoimmune demyelinating disorder that affects the peripheral nervous system, leading to sensory impairment. Anti-MAG-IgM antibodies... Read moreHematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read moreImmunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read moreMicrobiology
view channel
Handheld Device Deliver Low-Cost TB Results in Less Than One Hour
Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more
New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
Drug-resistant infections, particularly those caused by deadly bacteria like tuberculosis and staphylococcus, are rapidly emerging as a global health emergency. These infections are more difficult to treat,... Read more
Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read morePathology
view channel
Advanced Imaging Reveals Mechanisms Causing Autoimmune Disease
Myasthenia gravis, an autoimmune disease, leads to muscle weakness that can affect a range of muscles, including those needed for basic actions like blinking, smiling, or moving. Researchers have long... Read more
AI Model Effectively Predicts Patient Outcomes in Common Lung Cancer Type
Lung adenocarcinoma, the most common form of non-small cell lung cancer (NSCLC), typically adopts one of six distinct growth patterns, often combining multiple patterns within a single tumor.... Read moreIndustry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more